Jan. 2022, Series-C financing of $100 million completed.

Led by Goldman Sachs Asset Management and Sofina, with participation from Novo Holdings, Oiming Venture Partners, IDG Capital, LYFE Capital, GT Capital, and Cowin Capital.

Jan. 2022, 2021 China Venture • VIGOROUS 100 Ranking List. 

Feb. 2021, Series-B financing of $70 million completed.

Led by Qiming Venture Partners and IDG Capital, with participation from CMB International, GP Capital, Cash Capital, and Hangzhou Fulin Investment Partnership.

Dec. 2021, The first batch of  R&D and innovation enterprises in Lin-gang Special Area in 2021.

Jan. 2020, Hansoh Pharma's Excellence in Cooperation Award.

Mar. 2020, Series-A financing of $ 55 million.

This round of financing was led by LYFE Capital, with participation from IDG Capital, Cowin Capital, Korea Investment Partners (KIP), GT Capital and Shanghai Growth-FOF.

Jun. 2020, 2020 "Three Hundreds" Enterprise in Fengxian.

Oct. 2020, Shanghai Federation of Industry and Commerce Membership Certificate.

Nov. 2020, Pharma BIG Star Rising Star of Chinese Biomedicine CDMO Enterprise in 2020.

Dec. 2020, Bioindustry List of Climbers.

Dec. 2020, 2020 Zero2IPO Venture50 • Top 50 Growing Companies & Top 50 Medical Companies. 

Apr. 2020, Zhoupu Pudong Zencore Development Center is newly established at International Medical Zone.

Jun. 2020, Lin-gang Life Science Blue Bay launched Zencore ADC service.

Sep. 2020, Lin-gang Life Science Blue Bay (3× 2,000L / 3× 5,000L) laid foundation for GMP Commercial manufacturing facility in Lin-gang.

Sep. 2020, Lin-gang Life Science Blue Bay (2× 200L / 1× 500L) GMP pilot plant initiating operation 200 metric tons/year, cGMP medium manufacturing line production started.

Dec. 2019, Certification of "High and New Technology Enterprise".

Jan. 2018, One-stop-shop CDMO Service launched in Zhangjiang Shanghai.

Nov. 2017, Zencore was founded.